Technology

The AeroRx Therapeutics CEO discusses new treatments and how the industry at large is reacting to them.

The Google Cloud director discusses AI implementation and workflow.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

Bridging the last mile to clinical actionability.

Gene Mack, CEO of Gain Therapeutics, outlines the company’s strategic approach to advancing GT-02287 through potential collaborations and financing options as they await critical Parkinson’s disease trial data.

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and development, drugmakers can make more informed decisions and reduce the financial risks that drive up drug prices.

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, missed insights, and costly rework.

Webinar Date/Time: Thu, Aug 14, 2025 3:30 PM EDT

Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI so that pharma and biotech teams can better navigate the present time of uncertainty.

A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

The EVERSANA team discusses its new technology center that has a goal of pharmatizing AI.

Alliance Pharmaceuticals plans to use the new to attack counterfeiters rather than just defend against them.

Webinar Date/Time: Mon, Jul 28, 2025 11:00 AM EDT

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

The new platform integrates PCR-based diagnostic data with statistical modeling and AI to provide real-time visibility into infectious disease trends at local and global levels.

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, discusses the importance of collaboration across the healthcare community to develop inclusive and effective AI solutions that enhance decision-making and patient outcomes in oncology.

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

Prioritizing deeper customer insights helps life sciences marketers understand how to engage their HCP audiences effectively with the right message.

Research has shown a gap between the female patient experience compared to those of men.

The protection and privacy of healthcare data is a massive hurdle for the new technology to overcome.

Meeting the growing need and demand for fast information to make optimal and timely treatment decisions.